[Special Stock] Smooth Progress in New Drug Candidate Development... Qurient Up Over 5%

Curient's stock price is on the rise as it smoothly develops its major pipelines (new drug candidates) based on stable financial strength.

As of 9:48 a.m. on the 24th, Curient was trading at 9,170 KRW on the KOSDAQ market, up 470 KRW (5.40%) from the previous trading day.

On this day, Bukuk Securities evaluated Curient, stating, "The development of major pipelines (new drug candidates) is progressing smoothly. Stable research and development will be possible based on sufficient financial strength."

Researcher Daewoong Yoo of Bukuk Securities said, "The main new drug candidate Q901 (a CDK7 inhibitor, a drug that suppresses cell proliferation) is expected to have a synergistic effect when administered together with Top1i-ADC (an antibody-drug conjugate that attacks only specific cancer cells)." He added, "We confirmed the synergistic effect of combination therapy in various HER2 (a protein found in breast cancer and others) expression environments, and the second phase of clinical phase 1 is currently underway."

Researcher Yoo noted, "Curient's Q901 clinical trial is being administered according to the dosing cycle of the ADC drug, expected to conclude by mid-year, with results anticipated to be announced at academic conferences in the second half of the year." Another noteworthy new drug candidate, QP101 (Top1i x Q901), is a drug with two active substances (dual payload) and holds potential for expansion into a CDK7 inhibitor-based platform business.

Meanwhile, according to the schedule of the World Health Organization (WHO)-hosted meeting on tropical neglected skin diseases held over three days starting today, interim data on the Australian Phase 2 clinical trial for Buruli ulcer (a tropical skin disease) is expected to be released on the afternoon of the 25th. Researcher Yoo explained, "Following this, it is expected to enter an expanded clinical trial and proceed with the conditional approval process from the U.S. Food and Drug Administration (FDA). Upon approval, priority review voucher (PRV) and royalty (technology fee) receipts are anticipated."

The financial situation is also favorable. Researcher Yoo stated, "As of the end of last year, cash reserves were approximately 49 billion KRW, and considering annual operating expenses in the 20 billion KRW range, the possibility of shareholder value dilution due to fundraising is low for the time being." He evaluated, "The decision on the third-party allotment paid-in capital increase to the largest shareholder Dongkoo Bio & Pharma on the 14th is not only capital expansion but also a positive outlook on R&D new drug candidates."

This content was produced with the assistance of AI translation services.